Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) by 9.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 24,639 shares of the biopharmaceutical company’s stock after acquiring an additional 2,117 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Intra-Cellular Therapies were worth $2,058,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the business. Avior Wealth Management LLC raised its position in Intra-Cellular Therapies by 3.0% in the third quarter. Avior Wealth Management LLC now owns 4,473 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 131 shares in the last quarter. M&T Bank Corp raised its position in Intra-Cellular Therapies by 2.2% in the fourth quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock worth $526,000 after acquiring an additional 138 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in Intra-Cellular Therapies by 1.6% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 141 shares in the last quarter. CIBC Asset Management Inc raised its position in Intra-Cellular Therapies by 5.3% in the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock worth $247,000 after acquiring an additional 150 shares in the last quarter. Finally, Pallas Capital Advisors LLC raised its position in Intra-Cellular Therapies by 6.4% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock worth $266,000 after acquiring an additional 192 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Trading Down 0.1 %

Intra-Cellular Therapies stock opened at $131.26 on Monday. The stock has a 50-day moving average price of $123.95 and a 200 day moving average price of $95.70. Intra-Cellular Therapies, Inc. has a 52 week low of $63.87 and a 52 week high of $131.40. The stock has a market cap of $13.96 billion, a PE ratio of -150.87 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The business had revenue of $199.22 million during the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. On average, equities analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current year.

Analyst Ratings Changes

ITCI has been the subject of several research analyst reports. Piper Sandler reiterated a “neutral” rating and issued a $132.00 price objective (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Cantor Fitzgerald upgraded Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 14th. Leerink Partnrs cut Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Canaccord Genuity Group cut Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price target for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Finally, Needham & Company LLC restated a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Ten investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $106.08.

Intra-Cellular Therapies Company Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.